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Abstract
Background: To date, few studies have focused on the clinical and allergic characteristics of asthma in the elderly,
defined as asthma in people aged 60 or over. Thus, we propose to identify and study the clinical and allergic
characteristics and comorbidities of patients with asthma among the elderly.
Methods: A retrospective, observational, descriptive study was developed in five clinics and hospitals in Argentina.
Allergy Physicians analyzed their patients’ medical records in 2014 and included those adults over the age of 60, who
had been diagnosed with asthma according to the GINA guidelines. Clinical and allergic characteristics were analyzed.
Results: A total of 152 patients diagnosed with asthma, of whom 73% were women and 11% ex-smokers, were
included in this study, with a mean age of 66 years. Only 10.5% of the participants had onset asthma past the age
of 60. Regarding asthma severity, 74.3% were diagnosed with moderate persistent asthma, and 7.2% with severe
persistent asthma. Eighty-four percent of the patients were treated with an inhaled corticosteroid (ICS) along with a
long-acting β 2-adrenergic agent (LABA). More than half of the patients had two or more comorbidities simultaneously.
Allergic comorbidities were the most frequent comorbidities, followed by arterial hypertension. Among allergic
comorbidities, most patients presented allergies at the nasal level. There were no significant differences between the
subpopulations of patients with late-onset asthma (LOA) and asthma with onset before the age of 60, i.e. early onset
asthma (EOA) in most of their clinical characteristics. However, it was observed that EOA accounted for a higher
percentage of patients with nasal allergies as compared to LOA (71% vs 46%, p < 0.05).It is worth mentioning that
almost half of the patients with LOA had allergies at the nasal level.
Conclusion: These results may provide a better understanding of the clinical characteristics of asthma in the elderly in
Argentina, thus, enabling the development of future therapeutic strategies and a better quality of life for our elderly
asthma patients.
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Background
In the past, asthma was mainly considered a childhood
illness. However, recent epidemiological studies indicate
that new incident asthma can occur at any age, and it is
in fact highly prevalent in the older adult population and
its prevalence ranges from 4.5% to 12.7%. According to
the current demographic trends, a 100% increase in the
number of people over the age of 65 is expected in the
next 20 years [1, 2]. It would therefore be reasonable to
assume that there will be an increase in the impact of
asthma on the elderly in the near future. Likewise, the
burden of asthma is significantly higher in the elderly
than in the young, particularly in relation to mortality,
hospitalization, medical costs, and quality of life. How-
ever, asthma in the elderly is often underdiagnosed and
undertreated [1, 2].
The mainstay of asthma management at any age is to
achieve and keep the disease under control. The
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pharmacological control depends on the clinical and aller-
gic characteristics of the disease, and, in addition, symp-
toms may be influenced by age-related factors such as an
increased frequency of comorbidities and patients pre-
scribed with multiple drugs simultaneously. In addition,
specific problems associated with the management of
asthma in the elderly have been described, such as
improper use of the inhaler, poor adherence to treatment,
increased adverse effects, and declining response to medi-
cations. The study of the clinical characteristics of asthma
in the elderly is of utmost importance in terms of provid-
ing evidence to identify those diagnostic and therapeutic
methods that are safe and effective [1, 3].
Comorbidities are considered to be some of the key
characteristics of geriatric patients and contribute to the
clinical complexity of the elderly. In addition, they con-
tribute to poor asthma management outcomes in this
group as compared to younger asthmatic patients. The
presence of comorbidities has been shown to influence
the quality of life of the elderly with asthma, which in
turn affects adherence to treatments. In this context,
specific comorbidities may also prevent the correct use
of inhaler devices, for example, in patients suffering
from arthritis, orthodontics, dementia, etc [3, 4].
Knowing the epidemiology of asthma is essential for the
planning of health services, but our knowledge about this
disease is still incomplete. Historically, clinical studies on
asthma have frequently excluded the elderly population,
and there are still few observational epidemiological
studies which could shed light on the nature or the patho-
physiology of the disease. Consequently, it is imperative to
study the clinical and allergic characteristics of asthma in
the elderly, on the one hand, and their comorbidities, on
the other hand, in order to propose new therapeutic and
diagnostic strategies, and ultimately, to improve the
patients’ quality of life [1, 5].
Therefore, we aim to identify and study the clinical
and allergic characteristics, as well as the medical and
allergic comorbidities of asthma in patients over the age
of 60 in Argentina.
Methods
A retrospective, observational, descriptive study was de-
veloped in five clinics and hospitals in Argentina: Allergy
and Respiratory Diseases Research (InAER), Autono-
mous City of Buenos Aires, Argentina; Hospital Area
General De Agudos Dr. Ricardo Gutierrez, La Plata,
Argentina; Allergy and Immunology Service, Hospital
San Roque, Cordoba, Argentina; Private Medical
Centers, Ramos Mejia, Buenos Aires, Argentina.
Allergists analyzed their patients’ medical records for
three months in 2014, and included those aged 60 or
older diagnosed with asthma, according to the GINA
guidelines. It should be noted that some patients did not
present reversibility in the cross-section of this study, al-
though prior to the diagnosis of asthma they did present
it, according to the GINA guidelines.
For each asthmatic patient over 60 years, researchers
gathered the following information: 1) age, sex and race;
2) smoking status; 3) age at the onset of asthma, defined
as the age at which the patient is diagnosed with asthma;
4) asthma severity (according to the GINA guidelines);
6) Pulmonary function values; 7) positive reaction to the
Skin Prick Test (SPT) (mites, cats, dogs, aeroallergens,
pollen); 8) exacerbation triggers (exercise, tobacco
smoke, occupational, NSAIDs, menstruation, allergens);
9) total serum IgE (IgE ˃ 100 UI/ml were considered
subjects with high IgE); 10) eosinophil count (eosinophil
count in the peripheral blood of ≥500 eosinophils/μl were
considered eosinophilic subjects),; 11) current treatment
they receive; 12) dose of inhaled corticosteroids; 13)
Medical comorbidities (hypertension, gastroesophageal
reflux (GERD), dyslipidemia, coronary heart disease,
diabetes, pulmonary hypertension, other cardiovascular
diseases) and allergic conditions (seasonal allergic rhinitis,
perennial allergic rhinitis, allergic conjunctivitis, sinusitis,
chronic rhinosinusitis, nasal polyposis, eczema, chronic
urticaria, acute urticaria, intolerance to non-steroidal anti-
inflammatory drugs (NSAIDs), eosinophilic esophagitis).
Statistical analysis
Data are expressed as a percentage, except for the age of
onset and the time span with asthma, which are pre-
sented as mean and standard deviation (SD). The clinical
characteristics of the EOA and LOA subpopulations
were compared using unpaired Student t and Fisher’s
Exact Test, as appropriate. P values below 0.05 were
considered to be statistically significant.
Results
A total of 152 patients with a defined diagnosis of
asthma were included in this study, with a mean age of
66 (SD 6.5) years, of whom the majority were women
(73%). Regarding the racial characteristics of the partici-
pants, all of them were were Caucasian. None of the
patients were currently smokers, and only 11% had
previously smoked. The mean age of onset of asthma
symptoms was 33.4 (SD 22.9) years, with an average of
34.2 years (SD 21.9) (Table 1).
Late-onset asthma (LOA), defined as the onset of
asthma after the age of 60, was observed in 10.5% of the
patients, with a mean age of onset of 69.2 (SD 6.8) years,
having had asthma for an average of 7.3 (SD 4) years.
On the other hand, the mean age of onset of symptoms
in patients with asthma with an onset before the age of
60 (EOA) was 29 (SD 12.4) years, having had the disease
for 37.4 (21 years); both the age of onset of asthma and
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the time span with asthma were significantly different
between both subpopulations (p < 0.0001) (Table 1).
With regard to the severity of asthma, 74.3% of the pa-
tients were diagnosed with moderate persistent asthma,
15.7% with mild persistent asthma, 7.2% presented with
severe persistent asthma, and 2.6% with intermittent
asthma, with no statistical difference between the EOA
and LOA populations (Table 1).
The mean FEV1 (forced expiratory volume) was 73%,
and FEV1/forced vital capacity (FVC) was 69%. In
addition, 39% presented normal values of FEV1 (higher
than 80%), with 59% reversibility. Among the LOA
patients, we found that 50% had normal FEV1 (mean FEV1
of 71%), and 62% were reversible. While among the EOA
patients, 37% had normal FEV1 (mean FEV1 of 73%),
and 58% were reversible, with no statistical difference
between the EOA and LOA populations (Table 1).
Of all the patients tested on the SPT (72% of the
subjects), only 4% did not present any positive response.
Among the allergens investigated, mites (70%), fungi
(58%) and pollen (32%) were included (Table 2).
Among the asthma exacerbation triggers reported by
the patients, tobacco smoke was predominantly found,
resulting from passive smoking (75%), exercise (39%)
and aeroallergens (21%). Also, 31% of the patients pre-
sented other triggers not included among the mentioned
ones, such as dyes, perfumes and temperature changes.
On the other hand, 4% of the patients did not present
any triggers (Table 3).
Among the EOA and LOA populations, there were no
significant differences in both positive SPT allergens and
exacerbation triggers (Tables 2 and 3).
IgE was elevated in 54% of the patients, with an
average of 181 IU/ml, and eosinophilia was detected in
53% of the patients, with an average of 6.1% of eosino-
phils in the blood, with no significant differences among
the EOA and LOA patients (Table 1).
Asthma treatment
Eighty-three percent of the patients were treated with
an inhaled corticosteroid (ICS) along with a long-
acting β-adrenergic agent. Sixty percent of all patients
used fluticasone and salmeterol, while 24% used bude-
sonide and formoterol. The ICS dose was greater than
1000 mg/day in 24% of the patients. On the other hand,
16% had not been prescribed any specific treatment for
asthma. The main rescue treatment option chosen by the
patients was fast-acting β-adrenergic agonists, with salbu-
tamol being the most widely used one (91%), and only a
few of the patients used ipratropium bromide. On the
other hand, 9% of the patients did not use any rescue
treatment. Among the EOA and LOA patients, no signifi-
cant differences were observed in terms of the treatments
used (Table 4).
Table 1 Demographic, clinical and functional data of the study subjects
All subjects LOA EOA p
Subjects, % 100 (n = 152) 10.5 (n = 16) 89.4 (n = 136)
Female, % 73% 74% 68% ns
Age, yrs 66 (SD 6.5) 76 (SD 7) 65 (SD 5) < 0.0001
Former Smokers 11% 6,2% 14,2% ns
Age of onset, yrs 33.4 (SD 22.9) 69.2 (SD 6.8) 29 (SD 12.4) < 0.0001
Asthma duration, yrs 34.2 (SD 21.9) 7.3 (SD 4) 37.4 (SD 21) < 0.0001
Asthma severity ns
severe persistent,% 7.2 13 7 ns
moderate persistent,% 74.3 75 74 ns
mild persistent,% 15.7 12 16 ns
Intermittent,% 2.6 0 3 ns
FEV1
1, % 73 (SD 21) 71 (SD 20) 73 (SD 21) ns
FVC/FEV1
2, % 69 (SD 12) 68 (SD 11) 70 (SD 12) ns
Subjects with normal FEV1, % 39 50 37 ns
Subjects with reversibility, % 59 62 58 ns
Subjects with high IgE, % 54 72 51 ns
IgE (UI/ml) 181 (SD 68) 183 (SD 70) 177 (SD 75) ns
Eosinophilic subjects, % 52 50 54 ns
Eosinophil count, % 6,1 6,3 4,3 ns
Data are expressed as mean ± SD if not otherwise stated
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Comorbidities
Thirty-six percent of the patients experienced three or
more comorbidities simultaneously, two comorbidities
were observed in 32%, one comorbidity in 26%, and only
6% of the patients did not present any comorbidities at
all. Allergic comorbidities were most frequently found
(65%), followed by hypertension (45%), GERD (16%),
diabetes (12%), obesity (9%), coronary diseases (8%),
osteoarthritis, arthritis (7%), hypothyroidism (7%), Cha-
gas disease (4%), and dyslipidemia (3%). Other comor-
bidities were also found, such as gastritis, celiac disease,
breast cancer and pulmonary hypertension, but only in a
few patients. There were no significant differences in the
percentages of these comorbidities between the EOA
and LOA patients (Table 5).
Among allergic comorbidities, patients mainly had
nasal allergies (68%). Among them, mainly perennial
rhinitis (23%), seasonal (18%) or chronic rhinosinusitis
(15%), and, in addition, some patients presented chronic
rhinosinusitis and perennial rhinitis simultaneously
(12%). Only a few patients had chronic rhinosinusitis
and seasonal rhinitis (1%). Other allergic comorbidities
were uncommon, such as allergic conjunctivitis, sinus-
itis, nasal polyposis, eczema, chronic or acute urticaria,
and intolerance to NSAIDs. Twenty-nine percent of the
patients did not present any of the comorbidities sought.
On the other hand, EOA patients represented a higher
percentage of patients with nasal allergies as compared
to LOA (71% vs 46%, p < 0.05). However, it is worth
noting that almost half of the patients with LOA had
chronic rhinosinusitis or allergic rhinitis. Among the
patients with EOA, we observed that a similar propor-
tion of patients had seasonal rhinitis, perennial rhinitis
and chronic rhinosinusitis (17, 23 and 15%, respectively),
while 13% had chronic rhinosinusitis and perennial rhin-
itis. Only a small percentage of patients had chronic rhi-
nosinusitis and seasonal rhinitis [1]. Likewise, there were
no significant differences in the proportions of patients
with seasonal rhinitis, perennial and chronic rhinosinusi-
tis, between the EOA and LOA populations (Table 6).
Discussion
Asthma in the elderly is a health problem that, despite
being frequent, ends up being both under identified and
under diagnosed, which leads to inconveniences in the
patient’s quality of life, and associated morbidity and
mortality [1, 2]. The results obtained from this popula-
tion demonstrate different phenotypic differences with
respect to that of young patients, which has potential
impact on the diagnosis and management of this
Table 2 Comparison of allergens between the total population
and LOA and OAE
All subjects LOA EOA P
Allergens
Mites, % 70 50 70 ns
Fungi, % 58 100 56 ns
Pollen, % 32 50 31 ns
None, % 4 0 4 ns
Table 3 Comparison of Asthma exacerbation triggers between
total population and LOA and EOA
All subjects LOA EOA P
Triggers
Tobacco smoke, % 75 63 73 ns
Aeroallergens, % 21 6 22 ns
Exercise, % 39 31 40 ns
Others, % 31 19 34 ns
None, % 4 13 3 ns
Table 4 Comparison of treatments between the total population
and LOA and OAE
All subjects LOA EOA P
Rescue treatment
Salbutamol, % 91 88 91 ns
Ipratropium bromide, % 1 0 1 ns
None, % 9 12 9 ns
Base treatment
Fluticasone and salmeterol, % 60 63 60 ns
Budesonide and formoterol, % 24 25 24 ns
None, % 16 12 17 ns
ICS dose greater than 1000 mg/day, % 24 25 23 ns
Table 5 Comparison of comorbidities between the total population
and LOA and OAE
All subjects LOA EOA p
Comorbidities
None, % 6 13 6 ns
3 or more, % 36 25 36 ns
2, % 32 31 32 ns
1, % 26 31 26 ns
Hypertension, % 45 50 45 ns
Allergic comorbidities, % 65 50 67 ns
GERD, % 16 0 18 ns
Obesity, % 9 6 10 ns
Diabetes, % 12 0 12 ns
Osteoarthritis, % 7 6 7 ns
Hypothyroidism, % 7 6 7 ns
Chagas disease, % 4 0 4 ns
Coronary diseases, % 8 6 8 ns
Dyslipidemia, % 3 0 4 ns
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population. The chances of multi-causality of symptoms
or physical dysfunctions are much more likely at this
age. The response to medications is also more difficult
to interpret. Consequently, a greater knowledge of its
epidemiology, its clinical characteristics, comorbidities
and treatment is indispensable [1, 2].
In this paper, we have been able to identify for the first
time the clinical characteristics and comorbidities of
elderly asthmatics in Argentina. To the best of our
knowledge, this is the first time that a study like this one
has been done in Argentina, as well as in Latin America.
As in other studies conducted in Italy, Japan and the
United States [5–8], in this study, women are more rep-
resented than men, which is possibly due to a higher
prevalence of women in the larger populations owing
to their greater longevity, or a greater diagnosis of
COPD in men, or other factors. Given the importance
of smoking in the pathophysiology of respiratory dis-
eases, it is important to note that there were no
current smokers in this population, and only 11% had
previously smoked.
For many years asthma in the older adult had been
considered non-atopic [9], but recent studies show that
it is also atopic, with percentages of allergies ranging
from 30 to 77% [7, 8, 10, 11]. In addition, a recent study
performed in the United States with a large population
of patients, reported a percentage of allergies of approxi-
mately 65% in elderly asthmatics, which is similar to that
observed in young asthmatic patients. In this sense, in
the population described in this study, only 4% of the
patients did not present any positive response to the
SPT. However, given that all patients were selected from
allergy practices, we cannot rule out the possibility of
selection bias It is important to note that 7% of this
population had positive SPT and severe persistent
asthma, being potential candidates for anti-IgE therapy.
In previous studies, similar percentages of adult
asthmatic populations could potentially be treated with
this therapy. Given these results, and as suggested by
Scichilone et al., the study of sensitivity to allergens in
elderly asthma patients could be recommended [12].
It is noteworthy that the mean values of IgE in this
population (181 IU/ml) and eosinophils (6.1%) were
higher than those reported in the study by Inoue et al.
(91 IU/ML and 0.5%, respectively) [5]. The eosinophil
count was also higher than that reported by Park et al.
[11]. One possible explanation may be that the patients
included in this study were mostly atopic, whereas in the
work of Inoue et al. and Park et al. they represent ap-
proximately half of them [5, 11].
On the other hand, the values obtained from FEV1
(73%), and FEV1/FVC (69%) were similar to those
obtained by Park et al. and Inoue et al., who reported
values of 75% and 66%, and 81% and 72%, for FEV1 and
FEV1/FVC, respectively. In both studies it was observed
that values are significantly lower than when compared
to non-elderly asthmatics. It is important to emphasize
that the population described in this study presents
an average age lower than the average age of the
patients described in the studies of Inoue et al. and
Park et al. (66 years vs 73 years and 70 years, re-
spectively), and the duration of the illness is much
longer (34.2 years vs 12.7 years and 11.8 years,
respectively). In this sense, Inoue et al. demonstrated
that asthma in the older adult is characterized by an
airway obstruction that is independent of age per se
and the duration of the disease [5, 11].
As with other populations of elderly asthma patients,
most patients are treated with ICS along with a long-
acting β-adrenergic agent [1, 6, 7]. Although in this
population, 16% of the patients do not have any specific
treatment prescribed for asthma, in other studies it has
also been observed that approximately 10% do not
receive any treatment [1, 6, 7].
Most patients presented comorbidities, as described
for older asthmatic adults [1]. However, unlike Milanese
et al. [6], one (26%), two (32%), or three or more comor-
bidities (36%) were found to be similar in the population
described here, with almost half of the patients present-
ing with two comorbidities.
However, the comorbidities found match what has
been previously reported for this population with a high
frequency of arterial hypertension and allergic comor-
bidities, and, to a lesser extent, diabetes mellitus, cardio-
vascular diseases, and osteoarthritis or arthritis [1, 6, 7].
Older patients with asthma are usually divided into two
groups: those who have had asthma since childhood
(EOA) and those who develop it in adulthood (LOA)
[9, 13, 14]. In our study, we divided them into those
who acquired asthma after the age of 60 (LOA) [14], and
those who acquired it before the age of 60 (EOA) in a
manner similar to that described by Battaglia et al. and
Braman et al. [9, 14]. Considering the previously described
association between allergic rhinitis and EOA, in this
population, the majority of EOA patients presented with
Table 6 Comparison of nasal allergies between the total
population and LOA and OAE
All subjects LOA EOA P
Nasal allergies 68 46 71 < 0.05
Chronic rhinosinusitis, % 15 7 15 ns
Seasonal rhinitis, % 18 20 17 ns
Perennial rhinitis, % 23 20 23 ns
Chronic rhinosinusitis
and Perennial rhinitis, %
12 0 13 ns
Chronic rhinosinusitis
and Seasonal rhinitis, %
1 0 1 ns
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allergic rhinitis or chronic rhinosinusitis (71%), with statis-
tically significant differences with respect to the LOA
population (46%). However, we also observed that almost
half of the patients with LOA presented with chronic rhi-
nosinusitis or allergic rhinitis [1, 15] without significant
differences in the proportions of patients with seasonal
rhinitis, perennial and chronic rhinosinusitis between both
subpopulations. This may be associated with an increasing
problem of allergic rhinitis in the older adult population.
In an epidemiological study of atopic asthma, the high
prevalence of allergic rhinitis and atopic dermatitis ob-
served in the young population with allergy was similar in
the elderly population [16]. Similarly, the prevalence of
allergic rhinitis among people aged 60-70 years in
Switzerland is around 13-15% [1]. On the other hand, it
has been described that subjects with EOA have a greater
irreversible airway obstruction compared to those with
LOA [5, 13, 17]. However, in this study we obtained
statistically similar values of FEV1, FEV1/FVC for both
populations, and, in addition, the percentage of patients
with normal FEV1 and reversibility was also similar. It is
important to note that in this study the proportion of
subjects with LOA was much lower as compared to EOA.
Moreover, in two studies comparing EOA vs LOA, the
FEV1 values obtained for the LOA population are similar
to those observed in this study, while the values
corresponding to EOA subjects are much lower than in
this study, which in comparison are significantly different
[9, 17]. In this regard, it is worth noting that in many of
the studies, EOA patients present the onset of asthma
during childhood, whereas in this study the average age of
onset of asthma in the EOA population was 29 years-old.
Besides, in one of these studies, both populations were
discriminated on the basis of the time they experienced
asthma (the cut-off limit is 26 years with asthma) rather
than at the onset age of asthma [17]. Our study has a
series of advantages, such as the large sample size, the uni-
formity in the gathering of information, and the staging
according to international asthma recommendations.
However, some limitations may also be listed. In our study
there was a predominance of women and Caucasian
population, which limits the generalization of the results
to other populations. Besides, the numbers of subjects are
especially small (n = 16) in the LOA group.
Recruitment was in Allergy Units, although many
asthmatics are also treated by primary care Physicians,
Pulmonologists and internists. Also, not all the popula-
tion had skin tests performed and/or diagnosis and
treatment of upper airway punctuated. On the other
hand, some of these patients may also display an
ASTHMA-COPD overlap syndrome [18]. Finally, since
the study design is transversal, we cannot infer causality
in the reported associations. In spite of this we can con-
clude that we have found a greater proportion of the
elderly population with atopic asthma and with more
comorbidities than in other developed countries. Like-
wise, the EOA and LOA patients included in this study
did not show significant differences in most of their
clinical and allergic characteristics studied. However,
there were differences in allergies at the nasal level,
which made it possible to identify the association be-
tween allergic rhinitis and EOA previously described [1].
Conclusions
These results may provide a better understanding of the
clinical characteristics of asthma in the elderly, and thus
enable the development of future therapeutic strategies
and a better quality of life for our elderly asthmatic
patients.
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